title: Effects of nonpeptide endothelin receptor antagonists in rats with reduced renal mass.
abstract: This study was set up to evaluate the long-term effects of nonpeptide endothelin (ET) antagonists in rats with renal mass reduction (RMR). In the first series of experiments, rats were administered bosentan (100 mg/kg/day) or the angiotensin-converting enzyme inhibitor cilazapril (10 mg/kg/day) for 14 weeks beginning 24 h after RMR. As expected, cilazapril completely prevented the development of hypertension, proteinuria, and renal structural damage. In contrast, bosentan had no influence on the development of proteinuria and renal structural damage, although it had a moderate antihypertensive effect and improved creatinine clearance. A second set of experiments was performed to assess whether Ro 48-5695, a very potent ET antagonist optimized from bosentan, could prevent the development of renal damage and reverse established renal damage. Rats received Ro 48-5695 (30 mg/kg/day) beginning either 24 h (prevention) before for 8 weeks, or 4 weeks (reversal) after RMR. Ro 48-5695 attenuated the hypertension and the decline of creatinine clearance when treatment was started at 24 h, but not when started at 4 weeks. Ro 48-5695 had no effect on proteinuria. These observations suggest that ET-receptor activation does not play a major role in the progression of glomerular sclerosis in this model of chronic renal failure.
authors.affiliation: Actelion Ltd., Allschwil, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Clozel
authors.forename: C
authors.initials: C
authors.lastname: Qiu
authors.forename: R
authors.initials: R
authors.lastname: Osterwalder
authors.forename: A
authors.initials: A
authors.lastname: Roeckel
authors.forename: P
authors.initials: P
authors.lastname: Bruneval
authors.forename: D
authors.initials: D
authors.lastname: Heudes
authors.forename: J P
authors.initials: JP
authors.lastname: Clozel
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology; D000077300:Bosentan; D017315:Cilazapril / Q000494:pharmacology; D065128:Endothelin Receptor Antagonists; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D007677:Kidney Function Tests; D008297:Male; D009929:Organ Size / Q000187:drug effects; D011507:Proteinuria / Q000139:chemically induced; D011743:Pyrimidines / Q000009:adverse effects / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017466:Receptors, Endothelin / Q000378:metabolism; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology*; D000096926:Benzenesulfonamides
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D000077300:Bosentan; D017315:Cilazapril; D065128:Endothelin Receptor Antagonists; D011743:Pyrimidines; D017466:Receptors, Endothelin; D013449:Sulfonamides; C083751:Ro 46-2005; D000096926:Benzenesulfonamides